307 related articles for article (PubMed ID: 30961397)
1. Known epigenetic biomarkers for prostate cancer detection and management: exploring the potential of blood-based liquid biopsies.
Constâncio V; Barros-Silva D; Jerónimo C; Henrique R
Expert Rev Mol Diagn; 2019 May; 19(5):367-375. PubMed ID: 30961397
[TBL] [Abstract][Full Text] [Related]
2. Clinical utility of emerging biomarkers in prostate cancer liquid biopsies.
Boerrigter E; Groen LN; Van Erp NP; Verhaegh GW; Schalken JA
Expert Rev Mol Diagn; 2020 Feb; 20(2):219-230. PubMed ID: 31577907
[No Abstract] [Full Text] [Related]
3. Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions.
Hendriks RJ; van Oort IM; Schalken JA
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):12-19. PubMed ID: 27922627
[TBL] [Abstract][Full Text] [Related]
4. Early detection of the major male cancer types in blood-based liquid biopsies using a DNA methylation panel.
Constâncio V; Nunes SP; Moreira-Barbosa C; Freitas R; Oliveira J; Pousa I; Oliveira J; Soares M; Dias CG; Dias T; Antunes L; Henrique R; Jerónimo C
Clin Epigenetics; 2019 Dec; 11(1):175. PubMed ID: 31791387
[TBL] [Abstract][Full Text] [Related]
5. Liquid biopsy approach in the management of prostate cancer.
Riaz IB; Wang L; Kohli M
Transl Res; 2018 Nov; 201():60-70. PubMed ID: 29936077
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic Biomarkers in Cell-Free DNA and Applications in Liquid Biopsy.
Gai W; Sun K
Genes (Basel); 2019 Jan; 10(1):. PubMed ID: 30634483
[TBL] [Abstract][Full Text] [Related]
7. Multiparametric liquid biopsy analysis in metastatic prostate cancer.
Hodara E; Morrison G; Cunha A; Zainfeld D; Xu T; Xu Y; Dempsey PW; Pagano PC; Bischoff F; Khurana A; Koo S; Ting M; Cotter PD; Moore MW; Gunn S; Usher J; Rabizadeh S; Danenberg P; Danenberg K; Carpten J; Dorff T; Quinn D; Goldkorn A
JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30702443
[TBL] [Abstract][Full Text] [Related]
8. Clinical utility of emerging liquid biomarkers in advanced prostate cancer.
Vandekerkhove G; Chi KN; Wyatt AW
Cancer Genet; 2018 Dec; 228-229():151-158. PubMed ID: 28958406
[TBL] [Abstract][Full Text] [Related]
9. Extracellular vesicles for liquid biopsy in prostate cancer: where are we and where are we headed?
Minciacchi VR; Zijlstra A; Rubin MA; Di Vizio D
Prostate Cancer Prostatic Dis; 2017 Sep; 20(3):251-258. PubMed ID: 28374743
[TBL] [Abstract][Full Text] [Related]
10. Quick assessment of cell-free DNA in seminal fluid and fragment size for early non-invasive prostate cancer diagnosis.
Ponti G; Maccaferri M; Manfredini M; Micali S; Torricelli F; Milandri R; Del Prete C; Ciarrocchi A; Ruini C; Benassi L; Bettelli S; Kaleci S; Ozben T; Tomasi A
Clin Chim Acta; 2019 Oct; 497():76-80. PubMed ID: 31301282
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer.
Mollica V; Di Nunno V; Santoni M; Cimadamore A; Scarpelli M; Lopez-Beltran A; Cheng L; Mariani C; Battelli N; Montironi R; Massari F
Expert Rev Mol Diagn; 2020 Feb; 20(2):207-217. PubMed ID: 31640441
[No Abstract] [Full Text] [Related]
12. Circulating mRNA signature as a marker for high-risk prostate cancer.
Souza MF; Kuasne H; Barros-Filho MC; Cilião HL; Marchi FA; Fuganti PE; Rogatto SR; Cólus IMS
Carcinogenesis; 2020 Apr; 41(2):139-145. PubMed ID: 31305891
[TBL] [Abstract][Full Text] [Related]
13. Evaluating liquid biopsies for methylomic profiling of prostate cancer.
Silva R; Moran B; Russell NM; Fahey C; Vlajnic T; Manecksha RP; Finn SP; Brennan DJ; Gallagher WM; Perry AS
Epigenetics; 2020; 15(6-7):715-727. PubMed ID: 32000564
[TBL] [Abstract][Full Text] [Related]
14. Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges.
Trujillo B; Wu A; Wetterskog D; Attard G
Br J Cancer; 2022 Nov; 127(8):1394-1402. PubMed ID: 35715640
[TBL] [Abstract][Full Text] [Related]
15. Exosomal microRNAs as liquid biopsy biomarkers in prostate cancer.
Wang J; Ni J; Beretov J; Thompson J; Graham P; Li Y
Crit Rev Oncol Hematol; 2020 Jan; 145():102860. PubMed ID: 31874447
[TBL] [Abstract][Full Text] [Related]
16. Liquid biopsies for management of pancreatic cancer.
Samandari M; Julia MG; Rice A; Chronopoulos A; Del Rio Hernandez AE
Transl Res; 2018 Nov; 201():98-127. PubMed ID: 30118658
[TBL] [Abstract][Full Text] [Related]
17. Liquid biopsies: DNA methylation analyses in circulating cell-free DNA.
Zeng H; He B; Yi C; Peng J
J Genet Genomics; 2018 Apr; 45(4):185-192. PubMed ID: 29706556
[TBL] [Abstract][Full Text] [Related]
18. Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer.
Sumanasuriya S; Omlin A; Armstrong A; Attard G; Chi KN; Bevan CL; Shibakawa A; IJzerman MJ; De Laere B; Lolkema M; Lorente D; Luo J; Mehra N; Olmos D; Scher H; Soule H; Stoecklein NH; Terstappen LWMM; Waugh D; de Bono JS
Eur Urol Oncol; 2018 Jun; 1(2):151-159. PubMed ID: 31100240
[TBL] [Abstract][Full Text] [Related]
19. DNA Methylation-Based Testing in Liquid Biopsies as Detection and Prognostic Biomarkers for the Four Major Cancer Types.
Constâncio V; Nunes SP; Henrique R; Jerónimo C
Cells; 2020 Mar; 9(3):. PubMed ID: 32150897
[TBL] [Abstract][Full Text] [Related]
20. Sensitive tumour detection and classification using plasma cell-free DNA methylomes.
Shen SY; Singhania R; Fehringer G; Chakravarthy A; Roehrl MHA; Chadwick D; Zuzarte PC; Borgida A; Wang TT; Li T; Kis O; Zhao Z; Spreafico A; Medina TDS; Wang Y; Roulois D; Ettayebi I; Chen Z; Chow S; Murphy T; Arruda A; O'Kane GM; Liu J; Mansour M; McPherson JD; O'Brien C; Leighl N; Bedard PL; Fleshner N; Liu G; Minden MD; Gallinger S; Goldenberg A; Pugh TJ; Hoffman MM; Bratman SV; Hung RJ; De Carvalho DD
Nature; 2018 Nov; 563(7732):579-583. PubMed ID: 30429608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
